Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single cell resolution
- Universidad de Navarra, Spain
- Clinica Universidad de Navarra, Spain
- Hospital Universitario de Salamanca, Spain
- Vall d'Hebron Hospital Universitari, Spain
- NavarraBiomed, Spain
Abstract
Early hematopoiesis is a continuous process in which hematopoietic stem and progenitor cells (HSPCs) gradually differentiate toward specific lineages. Aging and myeloid malignant transformation are characterized by changes in the composition and regulation of HSPCs. In this study, we used single cell RNA sequencing (scRNAseq) to characterize an enriched population of human hematopoietic stem and progenitor cells (HSPCs) obtained from young and elderly healthy individuals. Based on their transcriptional profile, we identified changes in the proportions of progenitor compartments during aging, and differences in their functionality, as evidenced by gene set enrichment analysis. Trajectory inference revealed that altered gene expression dynamics accompanied cell differentiation, which could explain age-associated changes in hematopoiesis. Next, we focused on key regulators of transcription by constructing gene regulatory networks and detected regulons that were specifically active in elderly individuals. Using previous findings in healthy cells as a reference, we analyzed scRNA-seq data obtained from patients with myelodysplastic syndrome (MDS) and detected specific alterations of the expression dynamics of genes involved in erythroid differentiation in all patients with MDS such as TRIB2. In addition, the comparison between transcriptional programs and gene regulatory networks (GRN) regulating normal HSPCs and MDS HSPCs allowed identification of regulons that were specifically active in MDS cases such as SMAD1, HOXA6, POU2F2 and RUNX1 suggesting a role of these TF in the pathogenesis of the disease. In summary, we demonstrate that the combination of single cell technologies with computational analysis tools enable the study of a variety of cellular mechanisms involved in complex biological systems such as early hematopoiesis and can be used to dissect perturbed differentiation trajectories associated with perturbations such as aging and malignant transformation. Furthermore, the identification of abnormal regulatory mechanisms associated with myeloid malignancies could be exploited for personalized therapeutic approaches in individual patients.
Data availability
All the single cell RNA sequencing data is available at Gene Expression Omnibus under accession number GSE180298. The scripts needed to replicate the analysis are deposited on GitHub:https://github.com/mainciburu/scRNA-Hematopoiesis
-
Single-cell, multi-omic analysis identifies regulatory programs in mixed phenotype acute leukemiaNCBI Gene Expression Omnibus, GSE139369.
Article and author information
Author details
Tamara Jiménez Solas
Funding
Instituto de Salud Carlos III
- Marina Ainciburu
- Teresa Ezponda
- Nerea Berastegui
- Ana Alfonso-Pierola
- Amaia Vilas-Zornoza
- Patxi San Martin-Uriz
- Diego Alignani
- Jose Lamo de Espinosa
- Mikel San Julian
- Tamara Jiménez Solas
- Felix Lopez
- Sandra Muntion
- Fermin Sanchez-Guijo
- Antonieta Molero
- Julia Montoro
- Guillermo Serrano
- Aintzane Diaz-Mazkiaran
- Miren Lasaga
- David Gomez-Cabrero
- Maria Diez-Campelo
- David Valcarcel
- Mikel Hernaez
- Juan Pablo Romero
- Felipe Prosper
Ministerio de Ciencia e Innovación (PhD fellowship FPU18/05488)
- Marina Ainciburu
Fundación Científica Asociación Española Contra el Cáncer (Investigador AECC award)
- Teresa Ezponda
H2020 Marie Skłodowska-Curie Actions (Grant Agreement No. 898356)
- Mikel Hernaez
Federación Española de Enfermedades Raras (PI17/00701,PI19/00726 and PI20/01308)
- Marina Ainciburu
- Teresa Ezponda
- Nerea Berastegui
- Ana Alfonso-Pierola
- Amaia Vilas-Zornoza
- Patxi San Martin-Uriz
- Diego Alignani
- Jose Lamo de Espinosa
- Mikel San Julian
- Tamara Jiménez Solas
- Felix Lopez
- Sandra Muntion
- Fermin Sanchez-Guijo
- Antonieta Molero
- Julia Montoro
- Guillermo Serrano
- Aintzane Diaz-Mazkiaran
- Miren Lasaga
- David Gomez-Cabrero
- Maria Diez-Campelo
- David Valcarcel
- Mikel Hernaez
- Juan Pablo Romero
- Felipe Prosper
Centro de Investigación Biomédica en Red de Cáncer (CB16/12/00489 and CB16/12/00225)
- Marina Ainciburu
- Teresa Ezponda
- Nerea Berastegui
- Ana Alfonso-Pierola
- Amaia Vilas-Zornoza
- Patxi San Martin-Uriz
- Diego Alignani
- Jose Lamo de Espinosa
- Mikel San Julian
- Tamara Jiménez Solas
- Felix Lopez
- Sandra Muntion
- Fermin Sanchez-Guijo
- Antonieta Molero
- Julia Montoro
- Guillermo Serrano
- Aintzane Diaz-Mazkiaran
- Miren Lasaga
- David Gomez-Cabrero
- Maria Diez-Campelo
- David Valcarcel
- Mikel Hernaez
- Juan Pablo Romero
- Felipe Prosper
Gobierno de Navarra (ERAPerMed MEET-AML 0011-2750-2019-000001; AGATA 0011-1411-2020-000010/0011-1411-2020-000011 and DIAN)
- Marina Ainciburu
- Teresa Ezponda
- Nerea Berastegui
- Ana Alfonso-Pierola
- Amaia Vilas-Zornoza
- Patxi San Martin-Uriz
- Diego Alignani
- Jose Lamo de Espinosa
- Mikel San Julian
- Tamara Jiménez Solas
- Felix Lopez
- Sandra Muntion
- Fermin Sanchez-Guijo
- Antonieta Molero
- Julia Montoro
- Guillermo Serrano
- Aintzane Diaz-Mazkiaran
- Miren Lasaga
- David Gomez-Cabrero
- Maria Diez-Campelo
- David Valcarcel
- Mikel Hernaez
- Juan Pablo Romero
- Felipe Prosper
la Caixa" Foundation " (GR-NET NORMAL-HIT HR20-00871)
- Marina Ainciburu
- Teresa Ezponda
- Nerea Berastegui
- Ana Alfonso-Pierola
- Amaia Vilas-Zornoza
- Patxi San Martin-Uriz
- Diego Alignani
- Jose Lamo de Espinosa
- Mikel San Julian
- Tamara Jiménez Solas
- Felix Lopez
- Sandra Muntion
- Fermin Sanchez-Guijo
- Antonieta Molero
- Julia Montoro
- Guillermo Serrano
- Aintzane Diaz-Mazkiaran
- Miren Lasaga
- David Gomez-Cabrero
- Maria Diez-Campelo
- David Valcarcel
- Mikel Hernaez
- Juan Pablo Romero
- Felipe Prosper
Cancer Research UK (C355/A26819)
- Marina Ainciburu
- Teresa Ezponda
- Nerea Berastegui
- Ana Alfonso-Pierola
- Amaia Vilas-Zornoza
- Patxi San Martin-Uriz
- Diego Alignani
- Jose Lamo de Espinosa
- Mikel San Julian
- Tamara Jiménez Solas
- Felix Lopez
- Sandra Muntion
- Fermin Sanchez-Guijo
- Antonieta Molero
- Julia Montoro
- Guillermo Serrano
- Aintzane Diaz-Mazkiaran
- Miren Lasaga
- David Gomez-Cabrero
- Maria Diez-Campelo
- David Valcarcel
- Mikel Hernaez
- Juan Pablo Romero
- Felipe Prosper
Fundación Científica Asociación Española Contra el Cáncer (Accelerator Award Program)
- Marina Ainciburu
- Teresa Ezponda
- Nerea Berastegui
- Ana Alfonso-Pierola
- Amaia Vilas-Zornoza
- Patxi San Martin-Uriz
- Diego Alignani
- Jose Lamo de Espinosa
- Mikel San Julian
- Tamara Jiménez Solas
- Felix Lopez
- Sandra Muntion
- Fermin Sanchez-Guijo
- Antonieta Molero
- Julia Montoro
- Guillermo Serrano
- Aintzane Diaz-Mazkiaran
- Miren Lasaga
- David Gomez-Cabrero
- Maria Diez-Campelo
- David Valcarcel
- Mikel Hernaez
- Juan Pablo Romero
- Felipe Prosper
Associazione Italiana per la Ricerca sul Cancro (Accelerator Award Program)
- Marina Ainciburu
- Teresa Ezponda
- Nerea Berastegui
- Ana Alfonso-Pierola
- Amaia Vilas-Zornoza
- Patxi San Martin-Uriz
- Diego Alignani
- Jose Lamo de Espinosa
- Mikel San Julian
- Tamara Jiménez Solas
- Felix Lopez
- Sandra Muntion
- Fermin Sanchez-Guijo
- Antonieta Molero
- Julia Montoro
- Guillermo Serrano
- Aintzane Diaz-Mazkiaran
- Miren Lasaga
- David Gomez-Cabrero
- Maria Diez-Campelo
- David Valcarcel
- Mikel Hernaez
- Juan Pablo Romero
- Felipe Prosper
Gobierno de Navarra (PhD fellowship 0011-0537-2019-000001)
- Nerea Berastegui
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Human subjects: The samples and data from the patients included in the study were provided by the Biobank of the University of Navarra and were processed according to standard operating procedures. Patients and healthy donors provided informed consent, together with consent for publication. The study was approved by the Clinical Research Ethics Committee of the Clinica Universidad de Navarra, following protocol # 2017.218.
Copyright
© 2023, Ainciburu et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 4,448
- views
-
- 600
- downloads
-
- 30
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single cell resolution
eLife 12:e79363.
https://doi.org/10.7554/eLife.79363
Further reading
-
- Computational and Systems Biology
- Microbiology and Infectious Disease
The Staphylococcus aureus clonal complex 8 (CC8) is made up of several subtypes with varying levels of clinical burden; from community-associated methicillin-resistant S. aureus USA300 strains to hospital-associated (HA-MRSA) USA500 strains and ancestral methicillin-susceptible (MSSA) strains. This phenotypic distribution within a single clonal complex makes CC8 an ideal clade to study the emergence of mutations important for antibiotic resistance and community spread. Gene-level analysis comparing USA300 against MSSA and HA-MRSA strains have revealed key horizontally acquired genes important for its rapid spread in the community. However, efforts to define the contributions of point mutations and indels have been confounded by strong linkage disequilibrium resulting from clonal propagation. To break down this confounding effect, we combined genetic association testing with a model of the transcriptional regulatory network (TRN) to find candidate mutations that may have led to changes in gene regulation. First, we used a De Bruijn graph genome-wide association study to enrich mutations unique to the USA300 lineages within CC8. Next, we reconstructed the TRN by using independent component analysis on 670 RNA-sequencing samples from USA300 and non-USA300 CC8 strains which predicted several genes with strain-specific altered expression patterns. Examination of the regulatory region of one of the genes enriched by both approaches, isdH, revealed a 38-bp deletion containing a Fur-binding site and a conserved single-nucleotide polymorphism which likely led to the altered expression levels in USA300 strains. Taken together, our results demonstrate the utility of reconstructed TRNs to address the limits of genetic approaches when studying emerging pathogenic strains.
-
- Computational and Systems Biology
Plasmid construction is central to life science research, and sequence verification is arguably its costliest step. Long-read sequencing has emerged as a competitor to Sanger sequencing, with the principal benefit that whole plasmids can be sequenced in a single run. Nevertheless, the current cost of nanopore sequencing is still prohibitive for routine sequencing during plasmid construction. We develop a computational approach termed Simple Algorithm for Very Efficient Multiplexing of Oxford Nanopore Experiments for You (SAVEMONEY) that guides researchers to mix multiple plasmids and subsequently computationally de-mixes the resultant sequences. SAVEMONEY defines optimal mixtures in a pre-survey step, and following sequencing, executes a post-analysis workflow involving sequence classification, alignment, and consensus determination. By using Bayesian analysis with prior probability of expected plasmid construction error rate, high-confidence sequences can be obtained for each plasmid in the mixture. Plasmids differing by as little as two bases can be mixed as a single sample for nanopore sequencing, and routine multiplexing of even six plasmids per 180 reads can still maintain high accuracy of consensus sequencing. SAVEMONEY should further democratize whole-plasmid sequencing by nanopore and related technologies, driving down the effective cost of whole-plasmid sequencing to lower than that of a single Sanger sequencing run.
